<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058825</url>
  </required_header>
  <id_info>
    <org_study_id>8713-HIMSUM</org_study_id>
    <nct_id>NCT00058825</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant for Hematologic Diseases</brief_title>
  <acronym>HIMSUM</acronym>
  <official_title>Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are being asked to participate in this study because they have a cancer in their&#xD;
      blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as&#xD;
      Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria. Any of these conditions could benefit&#xD;
      from an allogeneic stem cell transplant using a donor that is related to the patient.&#xD;
&#xD;
      Stem cells are created in the bone marrow. They grow into different types of blood cells that&#xD;
      the patient needs, including red blood cells, white blood cells, and platelets. In a&#xD;
      transplant, the patient's own stem cells are killed and then replaced by stem cells from the&#xD;
      donor.&#xD;
&#xD;
      Usually, patients are given very strong doses of chemotherapy prior to receiving a stem cell&#xD;
      transplant. However, because of the patient's condition, they have a high risk of&#xD;
      experiencing life-threatening treatment-related side-effects. Recently, some doctors have&#xD;
      begun to use chemotherapy that does not cause as many side-effects before patients receive a&#xD;
      transplant.&#xD;
&#xD;
      This research study adds CAMPATH 1H to a low-dose chemotherapy regimen, followed by an&#xD;
      allogeneic stem cell transplantation. We want to see whether adding CAMPATH 1H to the&#xD;
      transplant medications helps in treating the disease. We also want to see whether there are&#xD;
      fewer life-threatening side-effects from the treatment. CAMPATH 1H is a drug that is still&#xD;
      being studied. CAMPATH 1H stays active in the body for a long time after patients receive it,&#xD;
      which means it may work longer at preventing graft-versus-host-disease (GvHD) symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment begins, stem cells will be collected from the donor's blood or bone marrow.&#xD;
      The stem cells will be collected and frozen before we start to give the patient chemotherapy.&#xD;
&#xD;
      After admission to the hospital, patients will receive total body irradiation (very strong&#xD;
      x-rays that kill cells in the bone marrow), Fludarabine and Campath 1H prior to the stem cell&#xD;
      transplant (infusion of the donor's stem cells).&#xD;
&#xD;
      Starting 7 days after the transplant, the patient will be given G-CSF by subcutaneous&#xD;
      injection, until a blood test shows that numbers of granulocytes (a type of white blood cell)&#xD;
      in the blood are more than 1,000/uL. This is to help increase blood cell counts.&#xD;
&#xD;
      After transplantation, the patient will undergo several evaluations at different times. These&#xD;
      are standard evaluations and tests performed for any patient who has received a stem cell&#xD;
      transplant, as part of routine clinical monitoring.&#xD;
&#xD;
      We will also be looking at the patient's immune function (how the body protects itself to&#xD;
      prevent and fight infections and diseases). To do this, blood tests will be performed at&#xD;
      regular intervals (every 3 to 6 months) for 2 years.&#xD;
&#xD;
      Depending on how well the donor stem cells work in the body after the transplant, the patient&#xD;
      may receive one or more Donor Leukocyte Infusions (DLI). This is when leukocytes (a type of&#xD;
      white blood cell) collected from the same donor that provided the stem cells are given to the&#xD;
      patient through a central line into a vein.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual due to practice changes meant study would take too long to finish&#xD;
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant Related Mortality (TRM)</measure>
    <time_frame>100 days</time_frame>
    <description>Percentage of patients with transplant related mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in Days to ANC Engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism Engraftment of Greater Than 50%</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Disease</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft Versus Host Disease</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Relapse-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Engrafted With the Isolex/CLINIMACs System</measure>
    <time_frame>30 days</time_frame>
    <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Engraftment With the Isolex/CLINIMACs System</measure>
    <time_frame>30 days</time_frame>
    <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath 1H</intervention_name>
    <description>Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Day -5 to Day -2: Fludarabine 30 mg/m2.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Day 0: Donor stem cells infused.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506 (Tacrolimus) or Cyclosporine</intervention_name>
    <description>Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Diagnosis of myelodysplastic disorders; Fanconi's Anemia; Acute Myelogenous Leukemia&#xD;
             (including secondary); Acute Lymphoblastic Leukemia; Multiple Myeloma; Plasma Cell&#xD;
             Dyscrasia; lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia,&#xD;
             Chronic Lymphocytic Leukemia, and Hodgkin's Disease). Diagnosis of myelodysplastic&#xD;
             disorders which is not good risk by IPSS: Fanconi's Anemia; Acute Myelogenous Leukemia&#xD;
             (1st or subsequent relapse, or 2nd or subsequent CR, or refractory disease); Acute&#xD;
             Lymphoblastic Leukemia in 2nd or subsequent remission or relapse or refractory&#xD;
             disease; Philadelphia Chromosome-positive Chronic Myelogenous Leukemia (failed STI and&#xD;
             interferon); Multiple Myeloma (Stage II or III); Lymphoma; Chronic Lymphocytic&#xD;
             Leukemia (primary refractory or recurrent disease); Hodgkin's Disease (after relapse);&#xD;
             Hemophagocytic Lymphohistiocytosis (failed chemotherapy and/or anti-viral therapy);&#xD;
             bone marrow failure such as Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria;&#xD;
             PNH (failed prior therapies).&#xD;
&#xD;
          2. Conditions that increase treatment related mortality: (need one or more to be&#xD;
             eligible): Age &gt; / = 50 years; EF of less than 45%; DLCO less than 50% or FEVI 50-75%&#xD;
             of predicted value; Diabetes Mellitus; Renal Insufficiency (but creatinine clearance&#xD;
             not less than 25 mL/min); Prior recent history of systemic fungal infection; 3rd or&#xD;
             greater remission of AML or ALL; Significant Grade III or IV neurologic or hepatic&#xD;
             toxicity from previous treatment; More than 1 year from diagnosis (CML or Myeloma&#xD;
             patients ONLY); Multiple types of treatment regimens (equal to or more than 3);&#xD;
             Significant Grade III or IV neurologic or hepatic toxicity from previous treatment;&#xD;
             Prior autologous or allogeneic stem cell transplantation.&#xD;
&#xD;
          3. Haploidentical family member donor. This protocol is open to patients who lack a 5/6&#xD;
             or 6/6 HLA antigen-matched donor. Due to the increased risk of GvHD, patients with&#xD;
             Fanconi Anemia and a 5/6 HLA match will also be eligible.&#xD;
&#xD;
             For this protocol, the &quot;best&quot; donor will be defined as a first-degree haploidentical&#xD;
             family member who matches at the greatest number of MHC loci. Matching will be&#xD;
             determined by Class I and Class II DNA typing. The donor should be sufficiently&#xD;
             healthy as to not be at increased risk from the stem cell mobilization procedure.&#xD;
             Should more than one &quot;equally&quot; MHC-incompatible donor be identified, other selection&#xD;
             criteria will include: age and size of donor, CMV status, and sex. The Principal&#xD;
             Investigator will make final decisions.&#xD;
&#xD;
          4. Available healthy donor without any contraindications for donation.&#xD;
&#xD;
          5. Patient and/or legal representative and/or legal guardian able to understand and sign&#xD;
             consent.&#xD;
&#xD;
          6. Age between birth and 70 years.&#xD;
&#xD;
          7. Women of child-bearing potential must have a negative pregnancy test.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Pregnant, lactating or unwilling to use contraception.&#xD;
&#xD;
          2. HIV-positive patient.&#xD;
&#xD;
          3. Uncontrolled intercurrent infection.&#xD;
&#xD;
          4. Untreated blast crisis for CML.&#xD;
&#xD;
          5. Uncontrolled high-grade lymphoproliferative disease / lymphoma.&#xD;
&#xD;
          6. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater).&#xD;
&#xD;
          7. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater).&#xD;
&#xD;
          8. Hemodialysis dependent.&#xD;
&#xD;
          9. Active hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3X&#xD;
             upper limit of normal.&#xD;
&#xD;
         10. Unstable cerebral vascular disease and recent hemorrhagic stroke (less than 6 months).&#xD;
&#xD;
         11. Active CNS disease from hematological disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Carrum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine; The Methodist Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 11, 2003</study_first_submitted>
  <study_first_submitted_qc>April 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2003</study_first_posted>
  <results_first_submitted>September 23, 2015</results_first_submitted>
  <results_first_submitted_qc>September 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2015</results_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>George Carrum</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Campath</keyword>
  <keyword>stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stem Cell Transplant</title>
          <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stem Cell Transplant</title>
          <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="2" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Transplant Related Mortality (TRM)</title>
        <description>Percentage of patients with transplant related mortality</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant Related Mortality (TRM)</title>
          <description>Percentage of patients with transplant related mortality</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Days to ANC Engraftment</title>
        <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Days to ANC Engraftment</title>
          <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism Engraftment of Greater Than 50%</title>
        <description>Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Patients engrafted</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism Engraftment of Greater Than 50%</title>
          <description>Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days</description>
          <population>Patients engrafted</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft Versus Host Disease</title>
        <description>Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft Versus Host Disease</title>
          <description>Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft Versus Host Disease</title>
        <description>Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft Versus Host Disease</title>
          <description>Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Relapse-free Survival</title>
        <description>Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Relapse-free Survival</title>
          <description>Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="11.5" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Overall Survival</title>
        <description>Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Overall Survival</title>
          <description>Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="16.8" upper_limit="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Engrafted With the Isolex/CLINIMACs System</title>
        <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isolex</title>
            <description>The Isolex system was used for cell selection.</description>
          </group>
          <group group_id="O2">
            <title>CLINIMACs</title>
            <description>The CLINIMACS CD34 Reagent system was used for cell selection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Engrafted With the Isolex/CLINIMACs System</title>
          <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Engraftment With the Isolex/CLINIMACs System</title>
        <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isolex</title>
            <description>The Isolex system was used for cell selection.</description>
          </group>
          <group group_id="O2">
            <title>CLINIMACs</title>
            <description>The CLINIMACS CD34 Reagent system was used for cell selection.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Engraftment With the Isolex/CLINIMACs System</title>
          <description>Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="21"/>
                    <measurement group_id="O2" value="12" lower_limit="9" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected until 30 days after autologous transplants and until 100 days after allogeneic transplants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stem Cell Transplant</title>
          <description>Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.&#xD;
Campath 1H: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.&#xD;
Fludarabine: Day -5 to Day -2: Fludarabine 30 mg/m2.&#xD;
Stem Cell Transplant: Day 0: Donor stem cells infused.&#xD;
Total Body Irradiation (TBI): Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.&#xD;
FK506 (Tacrolimus) or Cyclosporine: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to engraft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to engraft</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Transfusion: Platelets</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain or Cramping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>GGT (Gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Carrum, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <email>GCarrum@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

